Table 10.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Intestine Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		34	23	46	45	68	70	73	81	111	107
Tx with Antirejection Treatments		25	13	32	28	46	24	34	45	41	48
Antibodies	Category Usage	48.0%	30.8%	40.6%	25.0%	17.4%	20.8%	47.1%	48.9%	36.6%	31.3%
	ALG	0.0%	0.0%	9.4%	3.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	0.0%	0.0%	0.0%	3.6%	0.0%	4.2%	0.0%	0.0%	2.4%	2.1%
	OKT3	48.0%	30.8%	34.4%	17.9%	17.4%	12.5%	44.1%	31.1%	34.1%	29.2%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	11.8%	17.8%	7.3%	6.3%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	5.9%	6.7%	0.0%	2.1%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	6.7%	0.0%	0.0%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	8.3%
Corticosteroids	Category Usage	100.0%	100.0%	90.6%	92.9%	93.5%	91.7%	85.3%	75.6%	80.5%	95.8%
	Steroids	100.0%	100.0%	90.6%	92.9%	93.5%	91.7%	85.3%	75.6%	80.5%	95.8%
Antimetabolites	Category Usage	0.0%	0.0%	0.0%	3.6%	0.0%	0.0%	0.0%	0.0%	2.4%	0.0%
	Cytoxan	0.0%	0.0%	0.0%	3.6%	0.0%	0.0%	0.0%	0.0%	2.4%	0.0%
	Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.